

Ascendiant Capital Markets LLC serves as Financial Advisor on \$12,500,000 Public Offering for Oragenics, Inc.

IRVINE, Calif., April 2, 2019 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the completion of a \$12,500,000 Public Offering for Oragenics, Inc. (NYSE American: OGEN) of Tampa, Florida.

Ascendiant served as the Financial Advisor on the transaction.

Oragenics intends to use the net proceeds of the offering to fund its AG013 research, clinical trials, pre-clinical development of the lantibiotics program, and for working capital and general corporate purposes.

About Oragenics, Inc.

Oragenics, Inc (NYSE American: OGEN) is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. The Company has established two exclusive worldwide channel collaborations with Intrexon Corporation (NasdaqGS: XON) and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. For more information, please visit www.oragenics.com

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.